Company Overview: Benitec Biopharma Ltd

About the Company

Benitec Biopharma Ltd
Facebook Tweeter Linkedin

Benitec Biopharma holds the dominant global patent position for expressed RNA interference (also called DNA-directed RNAi (ddRNAi)), placing the company in a commanding position for human therapies associated with specific genes and genetic disorders. The use of shRNA for use in humans falls under our patent estate.

Our patented technology, ddRNAi, overcomes many of the drawbacks of other gene silencing technologies. It is being developed in-house and out-licensed for therapies where gene silencing is indicated for cure or treatment.

Investor Toolkit

Company News

  • Benitec Biopharma Interim Report for the Nine Months Ended March 31, 2016

    SYDNEY, May 24, 2016 /PRNewswire/ — Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today lodged its Interim Report for the nine months ended March 31, 2016. The report includes the financial results and a review of operations...

  • Benitec Biopharma to Host Corporate Update Conference Call

    Conference Call and Live Audio Webcast Scheduled for Wednesday, 25 May 2016 at 8:00am AEST / Tuesday, 24 May at 6:00pm EDT SYDNEY, May 17, 2016 /PRNewswire/ — Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced that...

  • Benitec to present at the ASGCT 2016 Annual Meeting

    SYDNEY, April 25, 2016 /PRNewswire/ — Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW), a biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or ‘expressed RNAi’, today announced acceptance of five presentations at the...

  • Benitec’s Hepatitis B Therapy Reduces HBV DNA by 98.5% In Vivo

    SYDNEY, March 8, 2016 /PRNewswire/ — Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is pleased to announce that BB-HB-331, a DNA-directed RNA interference (ddRNAi) therapy targeting the hepatitis B virus (HBV), demonstrates robust and durable suppression of...

Email Subscription


Follow this blog

Get every new post delivered right to your inbox.

Email address